Aclaris Therapeutics (ACRS) Analyst & Key Data

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

13

Hold

3

Ratings

Updated Sep 12, 2026

Overall Rating

D+

DCF Score1.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$5.32

Median Target+97.37%

$10.50

Potential upside vs current price

DCF Value-115.68%

-$0.83

Potential downside vs current price

Current Stock Price

$5.32

Median Target+97.37%

$10.50

Potential upside vs current price

DCF Value-115.68%

-$0.83

Potential downside vs current price

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

13

Hold

3

Ratings

Updated Sep 12, 2026

Overall Rating

D+

DCF Score1.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$5.32

Median Target+97.37%

$10.50

Potential upside vs current price

DCF Value-115.68%

-$0.83

Potential downside vs current price

Current Stock Price

$5.32

Median Target+97.37%

$10.50

Potential upside vs current price

DCF Value-115.68%

-$0.83

Potential downside vs current price

Aclaris Therapeutics, Inc.